IL257872A - Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson's disease - Google Patents

Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson's disease

Info

Publication number
IL257872A
IL257872A IL257872A IL25787218A IL257872A IL 257872 A IL257872 A IL 257872A IL 257872 A IL257872 A IL 257872A IL 25787218 A IL25787218 A IL 25787218A IL 257872 A IL257872 A IL 257872A
Authority
IL
Israel
Prior art keywords
dihydroisoquinolin
ethanone
methylbutyl
dichlorophenyl
parkinson
Prior art date
Application number
IL257872A
Other languages
English (en)
Hebrew (he)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL257872A publication Critical patent/IL257872A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL257872A 2015-10-23 2018-03-05 Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson's disease IL257872A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562245391P 2015-10-23 2015-10-23
PCT/US2016/057447 WO2017070068A1 (en) 2015-10-23 2016-10-18 Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
IL257872A true IL257872A (en) 2018-06-03

Family

ID=57233858

Family Applications (1)

Application Number Title Priority Date Filing Date
IL257872A IL257872A (en) 2015-10-23 2018-03-05 Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson's disease

Country Status (13)

Country Link
CN (1) CN108137506A (zh)
AR (1) AR106332A1 (zh)
AU (1) AU2016341115A1 (zh)
CA (1) CA2999332A1 (zh)
DO (1) DOP2018000103A (zh)
EA (1) EA201890525A1 (zh)
EC (1) ECSP18030976A (zh)
IL (1) IL257872A (zh)
MX (1) MX2018004794A (zh)
PE (1) PE20181296A1 (zh)
PH (1) PH12018500859A1 (zh)
TW (1) TW201725199A (zh)
WO (1) WO2017070068A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI725408B (zh) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
MA54530A (fr) * 2018-12-18 2021-10-27 Lilly Co Eli Schémas posologiques pour l'utilisation de ly3154207 dans le traitement de troubles du système nerveux central dopaminergiques
TWI843678B (zh) * 2019-06-18 2024-05-21 美商美國禮來大藥廠 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物
US20240299375A1 (en) 2021-03-08 2024-09-12 Eli Lilly And Company Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
MX2023010542A (es) 2021-03-09 2023-11-24 Lilly Co Eli Uso de mevidaleno y otros moduladores alostéricos positivos d1 para ralentizar la progresión de la enfermedad de parkinson.
CN113264926A (zh) * 2021-05-31 2021-08-17 东北林业大学 一种牡荆素与利血平的共晶及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
AU2008223145A1 (en) * 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Tetrahydroisoquinoline compounds as modulators of the histamine H3 receptor
US20120252853A1 (en) * 2011-04-01 2012-10-04 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل

Also Published As

Publication number Publication date
CA2999332A1 (en) 2017-04-27
CN108137506A (zh) 2018-06-08
ECSP18030976A (es) 2018-05-31
PE20181296A1 (es) 2018-08-07
DOP2018000103A (es) 2018-10-31
AR106332A1 (es) 2018-01-03
WO2017070068A1 (en) 2017-04-27
TW201725199A (zh) 2017-07-16
PH12018500859A1 (en) 2018-10-29
AU2016341115A1 (en) 2018-04-12
EA201890525A1 (ru) 2018-09-28
MX2018004794A (es) 2018-06-19

Similar Documents

Publication Publication Date Title
IL257872A (en) Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson's disease
SG11201912154XA (en) Aadc polynucleotides for the treatment of parkinson's disease
IL265206B1 (en) Antisense oligonucleotides for the treatment of eye disease
IL258471A (en) 11,13-modified saxitoxins for the treatment of pain
HUE066253T2 (hu) Benzoazepin analógok a bruton tirozin kináz gátlószereként
IL263188B (en) Treatment for Parkinson's disease
IL259297A (en) Heterocyclic compounds for the treatment of disease
SI3298008T1 (sl) Kristalinična oblika spojine (S)-3-(4-(5-(2-ciklopentil-6-metoksi-piridin-4-IL)-(1,2,4)oksadiazol-3- IL)-2-etil-6-metil-fenoksi)-propan 1,2-diol
IL288521A (en) Processes and intermediates for the preparation of 2-(6,2-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-4,3-dihydroisoquinoline -2(1h)-yl]ethanone
IL249428B (en) A polymorphic form of n-[2-(6 fluoro-lh-indol-3-yl)ethyl]-3-(2, 2, 3, 3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of Alzheimer's
ZA201807944B (en) Treatment for parkinson's disease